Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06308822 Active, not recruiting - Clinical trials for Refractory Multiple Myeloma

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

Start date: June 19, 2018
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial tests how well JNJ-42756493 (erdafitinib) works in treating patients with tumors that have more copies of the FGFR gene than is normal (amplification). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply.

NCT ID: NCT06303167 Active, not recruiting - Clinical trials for Hematopoietic and Lymphoid Cell Neoplasm

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Start date: August 6, 2015
Phase: Phase 2
Study type: Interventional

This phase II MATCH treatment trial evaluates the effectiveness of osimertinib (AZD9291) in treating patients with cancer that has certain genetic changes called EGFR mutations. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of mutant forms of the EGFR protein, which play a key role in tumor cell growth. Osimertinib may cause tumor cell death and inhibit tumor growth in EGFR-overexpressing tumor cells, thereby stopping or slowing the spread of tumor cells.

NCT ID: NCT06202885 Active, not recruiting - Lymphoma Clinical Trials

CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy

Start date: October 1, 2023
Phase:
Study type: Observational

The goal of this retrospective study is to compare between the case cohort and control cohort. The case cohort consists of lymphoma patients treated with novel immunotherapy regimen including Chimeric antigen receptor T cell therapy, bispecfic antibody, and/or antibody-drug conjugate. The control cohort consists of lymphoma patients who received conventional chemotherapy as standard-of-care The main question[s] it aims to answer are: - Survival times - Response outcomes

NCT ID: NCT06170216 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Start date: January 10, 2023
Phase:
Study type: Observational

Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.

NCT ID: NCT06115824 Active, not recruiting - Clinical trials for Primary Central Nervous System Lymphoma

A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen

Start date: August 10, 2023
Phase:
Study type: Observational

This study was a single-centre, retrospective study that retrospectively collected first-line PCNSL patients receiving methotrexate-based chemotherapy ± orelabrutinib at Huashan Hospital of Fudan University. The study was divided into two retrospective cohorts, Cohort A was a cohort of patients receiving methotrexate-based chemotherapy alone, and Cohort B was a cohort of patients receiving methotrexate-based chemotherapy + orelabrutinib.

NCT ID: NCT06074107 Active, not recruiting - Clinical trials for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

Start date: June 12, 2020
Phase: Phase 2
Study type: Interventional

This is an open,single-arm,multicenter phase II clinical study to evaluate the efficacy and safety of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma. The study will be divided into two stages: phase Ⅱa and phase Ⅱb. Phase Ⅱa is an exploratory study, which mainly explores the safe and effective dose and the relationship between gene and protein markers and drug sensitivity. The main purpose of the phase Ⅱb study was to evaluate the Objective response rate of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma, and the secondary study was to evaluate the disease control rate, progression-free survival, time to response, duration of response, overall survival and safety tolerance of BEBT-908 for injection in the treatment of relapsed or refractory diffuse large B-cell lymphoma. The relationship between the biomarkers of BEBT-908 for injection and the efficacy and safety was evaluated.

NCT ID: NCT05972577 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Start date: June 2, 2021
Phase: N/A
Study type: Interventional

This clinical trial tests whether a geriatric optimization plan (GO!) works to improve survival in patients over 60 with a hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplant. GO! focuses on creating a tailored and specific plan for each patient to make changes in their daily lives. These may include changes to their diet, sleep, activity, medicines, or even referrals to other providers depending on the patient's needs. Studying survival and quality of life in patients over 60 receiving an allogeneic hematopoietic cell transplant may help identify the effects of treatment.

NCT ID: NCT05934045 Active, not recruiting - Clinical trials for ALK-Positive Anaplastic Large Cell Lymphoma

Deciphering the Role of Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

CIRComa
Start date: January 1, 2023
Phase:
Study type: Observational

The objective of thE project is to determine, whether circRNAs could be used as circulating prognostic and/or predictive biomarkers of ALK+ ALCL resistance to treatment and whether they can be exploited as therapeutic targets.

NCT ID: NCT05882305 Active, not recruiting - Clinical trials for EBV-associated Lymphomas

KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial

Start date: June 10, 2023
Phase: Early Phase 1
Study type: Interventional

The main purpose of this study is to determine the tolerability and feasibility of KSD-101 in patients with EBV-associated haematologic neoplasms,to observe the characteristics of dose-limiting toxicity (DLT)and to explore the range of effective dose.

NCT ID: NCT05856708 Active, not recruiting - Clinical trials for Primary Mediastinal Large B-cell Lymphoma (PMBCL)

CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

Start date: January 2003
Phase:
Study type: Observational

This is a retrospective, multicenter study designed to collect data on the diagnostic, therapeutic management and outcome of patients diagnosed with primary mediastinal lymphoma who have progressed or relapsed with central nervous system (CNS) involvement. Through this study, an international data set from 6 different countries will be collected on clinical factors, anti-lymphoma therapy administered alone or in conjunction with CNS prophylaxis, re-biopsy site information when available, dose intensity of lymphoma therapy received at recurrence, and patient outcome. In addition, to better characterize the pathologic features of this rare entity, a central pathologic review of the initial diagnosis and, if available, histologic confirmation of recurrence will be performed.